Achilles Therapeutics plc (ACHL)
NASDAQ: ACHL · IEX Real-Time Price · USD
1.250
+0.040 (3.31%)
At close: Mar 28, 2024, 4:00 PM
1.270
+0.020 (1.60%)
After-hours: Mar 28, 2024, 7:39 PM EDT

Achilles Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2022202120202019
Selling, General & Admin
21.1221.9711.14.7
Research & Development
57.2642.2222.639.07
Operating Expenses
78.3864.233.7313.78
Operating Income
-78.38-64.2-33.73-13.78
Other Expense / Income
-7.32-3.13-0.530.22
Pretax Income
-71.07-61.06-33.2-13.99
Income Tax
0.110.0400
Net Income
-71.18-61.1-33.2-13.99
Shares Outstanding (Basic)
392911
Shares Outstanding (Diluted)
392911
Shares Change
36.59%2587.54%66.03%-
EPS (Basic)
-1.82-2.13-31.14-21.79
EPS (Diluted)
-1.82-2.13-31.14-21.79
Free Cash Flow
-67.05-66.92-37.1-15.08
Free Cash Flow Per Share
-1.71-2.33-34.80-23.49
EBITDA
-67.38-57.77-32.42-13.69
Depreciation & Amortization
3.693.290.770.3
EBIT
-71.07-61.06-33.2-13.99
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).